regardless of PD-L1 status research hub

AUSTRAL trial: An open-label, multicenter, phase II study of radiotherapy followed by durvalumab (MEDI4736) and ceralasertib (AZD6738) in stage III NSCLC patients with thoracic relapses +/- oligometastases after PACIFIC regimen

This study looks at a new treatment for stage III lung cancer that has returned. It combines radiation therapy with two drugs, durvalumab and ceralasertib, to see how safe and effective this combination is for patients.